Last reviewed · How we verify
Background PAH Therapy
Background PAH Therapy is a Biologic drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Pulmonary arterial hypertension (PAH).
Background PAH Therapy refers to foundational pulmonary arterial hypertension treatment, typically involving vasodilators and/or endothelin receptor antagonists to reduce pulmonary vascular resistance.
Background PAH Therapy refers to foundational pulmonary arterial hypertension treatment, typically involving vasodilators and/or endothelin receptor antagonists to reduce pulmonary vascular resistance. Used for Pulmonary arterial hypertension (PAH).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care. -
Big-pharma sponsor
+3.0pp
Merck Sharp & Dohme LLC is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Background PAH Therapy |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Biologic |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This is a descriptive term for established PAH therapies used as a baseline or comparator in clinical trials, rather than a single novel drug entity. Background PAH therapy generally includes agents such as phosphodiesterase-5 inhibitors, endothelin receptor antagonists, or prostanoid analogs that work through different mechanisms to dilate pulmonary vessels and reduce right ventricular afterload.
Approved indications
- Pulmonary arterial hypertension (PAH)
Common side effects
Key clinical trials
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) (PHASE3)
- A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension (PHASE1)
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients (PHASE3)
- A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020) (PHASE3)
- A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) (PHASE3)
- Ultrasound-Guided Stellate Ganglion Block for Alzheimer's Disease (NA)
- A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Background PAH Therapy CI brief — competitive landscape report
- Background PAH Therapy updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Background PAH Therapy
What is Background PAH Therapy?
How does Background PAH Therapy work?
What is Background PAH Therapy used for?
Who makes Background PAH Therapy?
What development phase is Background PAH Therapy in?
Related
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Pulmonary arterial hypertension (PAH)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing